Curaleaf Holdings Inc
OTC:CURLF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (4.1), the stock would be worth $3.48 (1% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.1 | $3.52 |
0%
|
| 3-Year Average | 4.1 | $3.48 |
-1%
|
| 5-Year Average | 4.1 | $3.55 |
+1%
|
| Industry Average | 3.2 | $2.71 |
-23%
|
| Country Average | 6.6 | $5.68 |
+61%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
C
|
Curaleaf Holdings Inc
OTC:CURLF
|
4.8B USD | 4.1 | -5.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 17.4 | 44.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 8.8 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 6.3 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 6.2 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 7.4 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 5.9 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 160.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 5.3 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 4.2 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 4.3 | 16.8 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 3.8 |
| Median | 6.6 |
| 70th Percentile | 10.6 |
| Max | 259 067.6 |
Other Multiples
Curaleaf Holdings Inc
Glance View
Curaleaf Holdings Inc. is a prominent player in the burgeoning cannabis industry. With its roots firmly planted in Massachusetts, Curaleaf quietly grew from a regional entity into a nationwide powerhouse. The company's business model intricately intertwines cultivation, processing, and retail. Curaleaf's vertically integrated structure allows for end-to-end control of its product lifecycle, enhancing both quality assurance and profit margins. They meticulously nurture cannabis plants from seed to harvest, which are then transformed into a range of products, spanning from flower and oil concentrates to edibles and topicals. This comprehensive approach not only supports supply chain efficiency but also significantly bolsters brand consistency and customer satisfaction. Curaleaf's revenue streams flow primarily from its retail operations, where they operate an extensive chain of dispensaries across multiple states. Their strategic acquisitions and mergers have only expanded their footprint, allowing them to tap into diverse markets with varying regulatory landscapes. By establishing a strong retail presence, Curaleaf deftly navigates the complex regulatory frameworks governing cannabis sales, enhancing their market reach and consumer base. Additionally, the company has been proactive in pursuing partnerships and brand extensions, further diversifying its offerings and appealing to a broader audience. This multi-faceted strategy enables Curaleaf to capture a significant share of the growing demand for cannabis-related products, setting a robust foundation for sustained financial growth in an industry poised for expansion.